Patents Assigned to AstraZeneca AB
  • Patent number: 9441047
    Abstract: Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: September 13, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
  • Patent number: 9441046
    Abstract: Provided herein is are methods of increasing forced expiratory volume in one second (FEV1) in an asthma patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: September 13, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
  • Patent number: 9441037
    Abstract: Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: September 13, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
  • Patent number: 9428503
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: August 30, 2016
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Kurt Gordon Pike
  • Patent number: 9421213
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: August 23, 2016
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Johannes Wilhelmus Maria Nissink, Paul Turner
  • Patent number: 9402847
    Abstract: The present invention relates to a combination comprising (5)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof, hereafter “Compound (I)”, and a taxane. Taxanes include established cancer drugs such as docetaxel (Taxotere™) and paclitaxel (Taxol™). Such combinations may be useful in the treatment or prophylaxis of cancer. The invention also relates to a pharmaceutical composition comprising such Compound (I) and a taxane. The invention further relates to a method of treatment comprising the simultaneous, sequential or separate administration of Compound (I) and a taxane, to warm-blooded animal, such as man. The invention also relates to a kit comprising Compound (I) and a taxane, optionally with instructions for use.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: August 2, 2016
    Assignee: AstraZeneca AB
    Inventor: Barry Robert Davies
  • Patent number: 9394291
    Abstract: Disclosed are certain derivatives of benzoxazinone amides of formula (I), or pharmaceutically acceptable salts thereof, that act as mineralocorticoid (MR) receptor modulators that may reduce oxidative stress in endothelium and hence improve vascular function, to methods for their potential therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: July 19, 2016
    Assignee: AstraZeneca AB
    Inventors: Gavin O'Mahony, Michael Kossenjans, Karl Edman, Johan Kajanus, Karl Anders Hogner, Philip Cornwall, Andrew Turner
  • Publication number: 20160185754
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Application
    Filed: July 22, 2015
    Publication date: June 30, 2016
    Applicant: ASTRAZENECA AB
    Inventors: Jorgen BLIXT, Michael David GOLDEN, Philip John HOGAN, David Michael Glanville MARTIN, Francis Joseph MONTGOMERY, Zakariya PATEL, John David PITTAM, George Joseph SEPENDA, Christopher John SQUIRE, Nicholas Cartwright Alexander WRIGHT
  • Patent number: 9375432
    Abstract: The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof: which possess inhibitory activity against activating mutant forms of EGFR, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of the compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: June 28, 2016
    Assignee: AstraZeneca AB
    Inventors: David Yunzhi Li, Jiabing Wang, Zhenfan Yang, Qingbei Zeng, Xiaolin Zhang
  • Publication number: 20160176906
    Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 23, 2016
    Applicant: AstraZeneca AB
    Inventors: Robert Bruce Diebold, Thomas Woodrow Gero, Paul Grover, Shan Huang, Stephanos Ioannidis, Claude Afona Ogoe, Jamal Carlos Saeh, Jeffrey Gilbert VARNES
  • Patent number: 9371321
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating immunological disorders, cardiovascular disease, cancer, and other diseases, disorders or conditions associated with PI3K?.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: June 21, 2016
    Assignee: AstraZeneca AB
    Inventors: Edcon Chang, Christopher Smith, Xiaolun Wang, Michael B. Wallace
  • Publication number: 20160152623
    Abstract: There are disclosed certain 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one compounds of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 2, 2016
    Applicant: AstraZeneca AB
    Inventors: Tord Bertil INGHARDT, Petra JOHANNESSON, Ulrik JURVA, Erik MICHAËLSSON, Eva-Lotte LINDSTEDT-ALSTERMARK, Nicholas TOMKINSON, Jeffrey Paul STONEHOUSE, Li-Ming Gan
  • Publication number: 20160151373
    Abstract: The present invention relates to a combination comprising AZD5363, or a pharmaceutically acceptable salt thereof, and at least one androgen receptor signalling modulator selected from MDV-3100 (also known as enzalutamide), AZD3514, abiraterone (or an ester prodrug thereof: e.g. abiraterone acetate), and bicalutamide; or a pharmaceutically acceptable salt thereof. Each of these combinations may be useful in the treatment of cancer. The invention also relates to pharmaceutical compositions comprising such combinations, and further relates to methods of treatment comprising the simultaneous, sequential or separate administration of AZD5363, or a pharmaceutically acceptable salt thereof, with at least one androgen receptor signalling modulator as described above, to warm-blooded animal, such as a human for the treatment of cancer. The invention also relates to a kit comprising such combinations.
    Type: Application
    Filed: February 8, 2016
    Publication date: June 2, 2016
    Applicant: ASTRAZENECA AB
    Inventor: Barry Robert DAVIES
  • Publication number: 20160136140
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: August 31, 2015
    Publication date: May 19, 2016
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • Publication number: 20160137634
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: August 31, 2015
    Publication date: May 19, 2016
    Applicant: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Benedicte Delouvrie, Craig Steven Harris, Christine Marie, Paul Lambert-Van der Brempt, Gilles Ouvry, Gary Patrick Reid, David Berry, Gary Peter Tomkinson
  • Patent number: 9339472
    Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: May 17, 2016
    Assignee: AstraZeneca AB
    Inventors: Divyakant S. Desai, Bing V. Li
  • Publication number: 20160130249
    Abstract: The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C1-5alkylR3 (wherein R3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy; 2) C2-5alkenylR3 (wherein R3 is as defined hereinbefore); 3) C2-5alkynylR3 (wherein R3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
    Type: Application
    Filed: May 22, 2015
    Publication date: May 12, 2016
    Applicant: ASTRAZENECA AB
    Inventors: Andrew Peter Thomas, Elaine Sophie Elizabeth Stokes, Laurent Francois Andre Hennequin
  • Publication number: 20160113953
    Abstract: A method for treating NAFLD and/or NASH and suitable compositions for carrying out the method are claimed.
    Type: Application
    Filed: September 24, 2015
    Publication date: April 28, 2016
    Applicant: ASTRAZENECA AB
    Inventor: Karl Erik Goeran GANNEDAHL
  • Patent number: 9309267
    Abstract: The present invention relates to novel derivatives that are suitable as precursors to compounds that are useful for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. The compounds deriving from these precursors are useful in methods of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease by positron emission tomography (PET) as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. Furthermore, the present invention also discloses the precursor compounds in crystalline form.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 12, 2016
    Assignee: AstraZeneca AB
    Inventors: Seth Björk, Peter Johnström, Nils A. Nilsson, Katinka Ruda, Per M. Schou, Britt-Marie Swahn, Vern Delisser
  • Patent number: 9295644
    Abstract: The present invention relates to use of a composition for symptomatic relief, when needed, comprising, in admixture (a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and (b) a second active ingredient which is budesonide; for the manufacture of a medicament for use in the prevention or treatment of an acute condition of asthma and/or intermittent asthma and/or episodes in chronic asthma. The invention further relates to a method for prevention or treatment of an acute condition of asthma and/or intermittent asthma and/or episodes in chronic asthma by administering, by inhalation, a composition comprising the first and second active ingredients as defined previously.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: March 29, 2016
    Assignee: AstraZeneca AB
    Inventor: Tommy Ekström